Lipoprotein Apheresis Is an Optimal Therapeutic Option to Reduce Increased Lp(a) Levels

Clinical Research in Cardiology Supplements - Germany
doi 10.1007/s11789-019-00094-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

An Option to Reduce Transaction Costs

SIAM Journal on Financial Mathematics
Applied MathematicsNumerical AnalysisFinance
2011English

Commentary: Effects of Different Lipoprotein Apheresis Methods on Serum Protein Levels

Journal of Immunological Sciences
2018English

Lipoprotein-Associated Phospholipase A2(Lp-Pla2) as a Therapeutic Target to Prevent Retinal Vasopermeability During Diabetes

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2016English

Therapeutic Apheresis: Why?

Therapeutic Apheresis and Dialysis
HematologyNephrology
2015English

Lipoprotein Apheresis Efficacy, Challenges and Outcomes: A Descriptive Analysis From the UK Lipoprotein Apheresis Registry, 1989–2017

Atherosclerosis
Cardiovascular MedicineCardiology
2019English

Therapeutic Apheresis: A Single Center Experience

The Journal of Tepecik Education and Research Hospital
2011English

Is Tetrahydrobiopterin a Therapeutic Option in Diabetic Hypertensive Patients?

Integrated Blood Pressure Control
Internal MedicineCardiovascular MedicineCardiology
2010English

Aging, Disease, and Therapeutic Apheresis

Therapeutic Apheresis and Dialysis
HematologyNephrology
2018English

Hemorrhoids: Which Is the Best Therapeutic Option?

International Surgery Journal
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy